| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
Unlisted dialysis procedure, inpatient or outpatient |
122,885 |
11,439 |
$14.68M |
| 0821 |
|
682 |
324 |
$930K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
42,009 |
4,671 |
$415K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
19,179 |
2,405 |
$269K |
| J1756 |
Injection, iron sucrose, 1 mg |
20,128 |
5,962 |
$125K |
| J0887 |
Injection, epoetin beta, 1 microgram, (for esrd on dialysis) |
4,168 |
2,409 |
$86K |
| A4657 |
Syringe, with or without needle, each |
36,457 |
7,306 |
$64K |
| 90945 |
|
634 |
24 |
$42K |
| J0606 |
Injection, etelcalcetide, 0.1 mg |
594 |
50 |
$40K |
| 0250 |
|
8,834 |
733 |
$15K |
| 83970 |
|
2,497 |
2,453 |
$9K |
| J0604 |
Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
453 |
171 |
$8K |
| 90674 |
|
301 |
293 |
$5K |
| 85048 |
|
2,399 |
2,328 |
$3K |
| 90662 |
|
263 |
259 |
$3K |
| 82728 |
|
2,304 |
2,242 |
$2K |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
337 |
288 |
$1K |
| 90747 |
|
28 |
28 |
$1K |
| 83540 |
|
2,325 |
2,253 |
$1K |
| 83550 |
|
1,811 |
1,766 |
$1K |
| 85041 |
|
2,475 |
2,401 |
$675.09 |
| 82108 |
|
145 |
142 |
$445.43 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
523 |
517 |
$279.37 |
| 90670 |
|
41 |
41 |
$256.46 |
| 90661 |
|
45 |
45 |
$222.67 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
85 |
25 |
$189.35 |
| G0008 |
Administration of influenza virus vaccine |
418 |
413 |
$128.11 |
| 85045 |
|
116 |
104 |
$32.07 |
| 0302 |
|
278 |
254 |
$16.99 |
| G0010 |
Administration of hepatitis b vaccine |
12 |
12 |
$9.09 |
| G0009 |
Administration of pneumococcal vaccine |
38 |
38 |
$2.09 |
| 0771 |
|
12 |
12 |
$0.00 |